The 2017 Walter Wright annual ophthalmology review symposium will focus on glaucoma management by the comprehensive ophthalmologist: the most significant changes in the in the past decade as well as the most important trends occurring now.
World-renowned experts will update participants on the diagnosis and treatment of common glaucoma disorders. This meeting will feature an innovative and highly interactive format between the speaker and the audience, incorporating electronic polling and social media for real-time feedback. Speakers will be posed topical questions highly relevant to the day-to-day management of glaucoma. They will be challenged to deliver a key “pearl” or take-home-message that participants can immediately apply in their offices. In the spirit of friendly competition, the “pearls” delivered by speakers will be rated by the audience, and scores posted in real-time on a speaker “leaderboard”. At the end of the meeting, the top 10 pearls will be reviewed and discussed by a panel of comprehensive ophthalmologists and glaucoma specialists who will vote on the winner of the prestigious “COMA” award for the best glauCOMA pearl of the meeting.
Topics will include:
- EMR and glaucoma – how does it help manage a chronic disease over the course of decades or longer? Can I stay with paper until retirement?
- Home IOP-monitoring –ready for prime time yet?
- rNFL OCT progression with stable fields – should I change my therapy, and how? Is surgery indicated?
- Ganglion cell analysis with OCT – are the clinical correlations there yet?
- Evaluating narrow angles – do I need anterior segment OCT, or will tried-and-true gonioscopy still suffice?
- OCT angiography – if the retina doc has one anyway, should I start sending my glaucoma patients for testing?
- Marijuana and glaucoma – any disease benefits, other than making your patients less worried about going blind?
- Ocular surface disease and glaucoma – why this dry topic cannot be avoided
- COS glaucoma guidelines a decade later – What’s still current? What’s dated?
- Steroid responders – how do I minimize IOP spikes when treating chronic uveitis?
- Anti-VEGF’s – do they treat glaucoma, cause glaucoma, or both?
- Alphabet soup of proliferation in MIGS – what procedures should the comprehensive ophthalmologist pay the most attention to?
- Trabeculoplasty – should I buy a micropulse trabeculoplasty laser, or will SLT do just fine?
- Angle closure – when is it time to skip the LPI and head straight to cataract surgery?
- Trabs in the next decade – still a role when you gotta go real low, or time to retire the procedure?
- Cataract surgery in glaucoma patients – what is the right (and wrong) IOL choice?
Continuing Professional Development (CPD), Faculty of Medicine, University of Toronto, is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME), a subcommittee of the Committee on Accreditation of Canadian Medical Schools (CACMS). This standard allows CPD to review and assess educational activities based on the criteria established by The College of Family Physicians of Canada and the Royal College of Physicians and Surgeons of Canada.
As a result of a reciprocal agreement between the Royal College of Physicians and Surgeons of Canada, The American Medical Association, and The European Union for Medical Specialties (EUMS), CPD is permitted to assign respective credits.
Letters of Accreditation and Attendance
Letters of accreditation/attendance will be available online following the course. Participants will be e-mailed information within two weeks after completion of the course specifying how to obtain their letter of accreditation/attendance online. We do not routinely mail out accreditation letters.
It is the policy of University of Toronto, Faculty of Medicine, Continuing Professional Development to ensure balance, independence, objectivity, and scientific rigor in all its individually accredited or jointly accredited educational programs. Speakers and/or planning committee members, participating in University of Toronto accredited programs, are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships within the last FIVE (5) years with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of facts. It remains for the audience to determine whether the speaker's outside interests may reflect a possible bias in either the exposition or the conclusions presented.